Bergabunglah dengan Buletin Kami
Bergabunglah dengan daftar pelanggan kami untuk mendapatkan artikel terkini, update dan penawaran khusus langsung di kotak masuk Anda
The funding will be used for commercial readiness and the potential US launch of...
Approval grants eligibility for 180-day shared generic drug exclusivity The pos...
Study meets primary endpoints in chronic spontaneous urticaria across Europe an...
Recognition based on study covering subsidiaries and employee participation The...
Company aims to lower upfront cost to support early treatment initiation for re...
The project will enhance Aspect Biosystems’ clinical development capabilities an...
As AI reshapes pharma, HR leadership is being drawn into a deeper question that...
The approval in the European Union (EU) is for adults with platinum-resistant ep...
Beyond the semaglutide momentum, a larger wave of patent expiries is set to unf...
Weight management drug to be available from Rs 3,999 per month from April 3, 20...
Bharat Bhardwaj, Vice President, Asia Pacific, Agilent Technologies spoke to Vi...
Agilent Technologies has announced the opening of its Customer Experience Cente...
RYALTRIS is Glenmark’s first innovative product introduced into the US market T...
The integration of VISUfarma has expanded Lupin’s ophthalmology portfolio to ov...
This follows the company’s signing of a definitive agreement in October 2025 to ...
Under the agreement, Biocytogen’s fully human antibody discovery platform will b...
